Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923830 · ClinicalTrials.gov registry record · Phase 4
Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes
A Phase 4 study, sponsored by TriHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT02923830: Clinical Trial Phase 4 study, sponsored by TriHealth.
NCT02923830 is a Phase 4 study that was terminated before completion, run by TriHealth. The registered enrollment target is 28 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923830, a Phase 4 study, was terminated before completion, sponsored by TriHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in BioFlo implanted port catheters. The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients whose ports are flushed with a combination of saline and heparinized saline.
Primary Outcome
Number of Participants with Occurrence of First Complete Occlusion (Blockage) over the 1 year. The date of the first complete occlusion will be recorded.
Interventions
- OTHER Heparinized saline catheter flush
- DRUG Saline-only catheter flush
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 4 |
Why NCT02923830 stopped before completion
NCT02923830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Heparinized saline catheter flush is the first listed.
NCT02923830 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02923830 about?
NCT02923830 is a clinical study titled "Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes". The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in BioFlo implanted port catheters. The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients w...
What is the current status of trial NCT02923830?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2016-04. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT02923830?
The interventions under investigation include: Heparinized saline catheter flush (OTHER), Saline-only catheter flush (DRUG).
Who is sponsoring clinical trial NCT02923830?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02923830's enrollment target sits among peer trials
28 1635th of 2000 higher than 350 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia